Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Contact Us
AUA Advocacy Communications
10 G Street NE
Suite 600
Washington, D.C. 20002
1-866-RING-AUA (toll-free)
410-689-3810 (direct)
Email
Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems CY 2027 Final Rule Summary
On November 4, the Centers for Medicare & Medicaid Servies (CMS) released the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule for CY 2027. The rule makes payment and policy changes to services provided under the OPPS and ASC payment system including updating payment rates, continuing policy to phase out the inpatient only list, expanding prior authorization in traditional Medicare, and reducing payment for drugs acquired under the 340B program. The final rule is accompanied by a fact sheet and the addenda used by CMS in rate setting. Page numbers in this summary reflect the page number of the display copy of the final rule linked above.
Payment Rate Update Updates for OPPS and ASC Payment System – p. 73
Payment rates for services performed in the hospital outpatient department will increase by 2.3% in 2027. The increase, derived from the inpatient hospital market basket increase of 3.2% for inpatient services paid under the inpatient prospective payment system is then reduced by a productivity adjustment of 0.9%. The agency estimates that total Medicare payments to OPPS providers, including Medicare beneficiary cost sharing, will be $110.9 billion in 2027, an increase of $9.5 billion. Payment rates in the ASC setting will also increase by 2.3% and total payments will equal approximately $9.9 billion. Hospitals that do not meet quality reporting requirements will be subject to a 2% reduction in overall Medicare payments, while hospitals captured under the 340B remedy offset will see a reduction of 3%.
Permanent Prostatic Urethral Stent, CPT® Code 52282 (APC 5375) – p. 343
CMS reassigned CPT code 52282 (cystourethroscopy with insertion of a permanent urethral stent) from APC 5374 (Level 4 Urology and Related Services) with a CY 2027 payment rate of $4,064 to APC 5375 (Level 5 Urology and Related Services), with a payment rate of $$6,190. This change, January 1, 2027, increases Medicare outpatient hospital department payment for the procedure by 52%.
CMS concluded that the procedure reported by CPT code 52282 shares greater resource use and clinical similarity with procedures assigned to APC 5375, particularly HCPCS code C9739 - cystourethroscopy with insertion of one to three transprostatic implants. Additionally, CMS determined that the claims data for CPT code 52282 do not accurately reflect the costs of inserting a permanent prostatic urethral stent. Given the uncertainty, CMS will maintain payment at the level of APC 5375 until more representative data become available.
Background:
To evaluate OPPS payment for this service, CMS analyzed Medicare outpatient department claims for services associated with CPT code 52282 furnished between January 1, 2025, and December 31, 2025. Based on 109 claims, CMS determined that the geometric mean cost of the procedure was approximately $4,005. Even though CMS has claims data from 2025, the agency determined that prior years claims data did not accurately reflect the current costs of the procedure because there was no Food and Drug Administration (FDA)-approved permanent prostatic urethral stent available in the United States for approximately nine years. A new permanent prostatic urethral stent, the ProVee® System, received FDA premarket approval in late 2025.
CPT code 52282, which has been effective since 1998, describes cystourethroscopy with insertion of a permanent urethral stent using an endoscope. As noted in the rule, this procedure is intended to provide an additional treatment option for select patients with obstructive lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The new ProVee® System is indicated for men with prostatic urethral lengths of at least 3.75 cm and prostate volumes between 30 cc and 80 cc who have LUTS resulting from BPH.
Integrated Sacral Neurostimulator, CPT Code 0786T (APC 5464) – p. 455
Effective January 1, 2027, CMS reassigns CPT code 0786T from APC 5463 to APC 5464 (Level 4 Neurostimulator and Related Procedures). Because the code was not assigned to a clinical APC until January 1, 2026, no CY 2025 Medicare claims data were available to inform the APC assignment. Without claims data to inform CMS on appropriate APC placement for 0786T, the agency instead compared the procedure to existing sacral and tibial neuromodulation procedures for bladder dysfunction and concluded that the resources and clinical effort are like those associated with APC 5464. Therefore in 2027, the base payment rate for APC 5464 is $22,127 instead of the payment rate associated with APC 5463 which is $12,248.
Background:
Effective January 1, 2024, Category III CPT code 0786T (Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed) was created to distinguish implantation of integrated sacral neurostimulator systems from traditional sacral neurostimulator procedures reported with CPT code 64590 (Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver). Since the integrated neurostimulator device was not FDA approved at the time, CMS assigned CPT code 0786T a status indicator E1 (not covered under an outpatient benefit category). Following FDA approval of the Neuspera integrated sacral neurostimulator for urge urinary incontinence in June 2025, CMS finalized coverage for the procedure in the CY 2026 OPPS rule, assigning CPT code 0786T to APC 5463 (Level 3 Neurostimulator and Related Procedures) with status indicator J1 (Hospital Part B services paid through a comprehensive APC).[1]
APC Payment Rates for Cystourethroscopy Procedures – Addendum B
HCPCS code C9761 (Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, and ureteral catheterization for steerable vacuum aspiration of the kidney, collecting system, ureter, bladder, and urethra, if necessary, with use of steerable ureteral catheter or suction-integrated ureteroscope) maps to APC 5376 (Level 6 Urology and Related Services). The 2027 payment rate for APC 5376 is $10,688, and the service has a payment status indicator of J1.
HCPCS code C8014 (Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, including use of a suction enabled ureteral access sheath, with irrigation (if performed)) became effective July 1, 2026. This service maps to APC 5375 (Level 5 Urology and Related Services) with a payment rate of CY 2027 $6,190, and payment status indicator J1.
Alternative Pathway for New Technology Add-on Payment – p. 352 and p. 443
CMS finalized the proposal to eliminate the alternative pathway that allows FDA Breakthrough Devices to qualify for OPPS transitional device pass-through payment, with one limited exception. According to CMS, while FDA Breakthrough Device designation reflects eligibility for the FDA's expedited review program, it does not necessarily demonstrate that a device satisfies Medicare's separate requirement to show substantial clinical improvement for a new technology payment designation.
CMS finalized a limited exception for a new device that has already received FDA Breakthrough Device designation as of September 30, 2026, in which the FDA Breakthrough Device will remain eligible for pass-through payment under the alternative pathway with applications continuing to be accepted for CY 2028 and CY 2029. CMS must receive a complete application for eligible devices under this limited exception no later than March 1, 2028.
As outlined in the final rule, beginning with applications submitted on or after October 1, 2026, manufacturers will be required to satisfy all existing pass-through eligibility criteria currently reflected at § 419.66(c)(2)(i), which include demonstrating substantial clinical improvement, rather than relying on FDA Breakthrough Device designation. Pass-through payment applications for FDA Breakthrough Devices submitted by September 30, 2026, will continue to be evaluated under the current alternative pathway, provided that all other criteria have been met, and existing pass-through categories established under that pathway will continue to be eligible for pass-through payment and remain in effect for at least 2 years, but no more than 3 years, consistent with § 419.66(g).
Payment Adjustment for 340B-Acquired Drugs – p. 634
Before proposing policy changes to the 340B drug pricing program, CMS conducted a nationwide survey of hospital acquisition costs for each separately payable drug paid by Medicare through the OPPS. After considering public comments and considering the hospital acquisition cost survey data, the agency finalized its alternative proposal to reduce Medicare reimbursement for 340B-acquired drugs to ASP minus 28%, which is based on 340B ceiling price data instead of the survey data alone. Typically, 340B-acquired drugs are paid at ASP plus 6%. To learn more about the data analysis of the survey and the methodology CMS used to arrive at the 28% reduction, the agency provides a lengthy, highly detailed explanation starting on page 634 of the final rule.
The 340B Drug Pricing Program established by Congress in 1992 to enable eligible safety-net health care providers to purchase certain outpatient drugs from manufacturers at discounted prices. Participating drug manufacturers are required to provide discounts on covered outpatient drugs as a condition of participation in the Medicaid Drug Rebate Program, while the hospitals captured under the program are expected to use the savings to enhance patient care and maintain access to health care services.
CY 2027 Changes to the Inpatient Only List – p. 749
In the final rule, CMS continues towards complete elimination of the inpatient only (IPO) list with implementation of the second phase of the process by removing 637 procedures from the IPO in the following clinical families: auditory, digestive, endocrine, female genital, hemic and lymphatic systems, integumentary, male genital, maternity care and delivery, mediastinum and diaphragm, respiratory, and urinary. CMS finalized the policy in the 2026 OPPS rule to discontinue the IPO list beginning in 2026 by using a phased-in approach, with the list being eliminated by January 1, 2029. CMS expects that the remaining clinical families and services will be removed from the IPO list for CY 2028, during the third and final phase of the elimination.
The IPO list was established in 2000 as part of the implementation of the OPPS. The IPO list identified procedures that Medicare only reimbursed when performed in a hospital inpatient setting due to certain factors of the procedure including the invasiveness of the procedure, the health status of the beneficiary, and postoperative recovery time. However, as stated in last year’s rule, CMS notes that changes in medical technology, the development of advanced surgical techniques, and quality and safety advances have made the use of the IPO list unnecessary. Additionally, CMS recognizes that physicians are best positioned to determine the most appropriate and safest site of service for a procedure based on their clinical expertise, professional judgment, and the individual needs of the Medicare beneficiary.
Payment for Imaging without Contrast Services for CY 2027 and Subsequent Years – p. 793
With this final rule, CMS continues its efforts to control unnecessary increases in the volume of outpatient services furnished in excepted off-campus provider-based departments (PBDs). CMS will cap payment for certain imaging services at the amount paid under the Medicare Physician Fee Schedule (MPFS). However, rural Sole Community Hospitals (SCHs) are exempt from this site-specific MPFS-equivalent payment policy for HCPCS codes assigned to the imaging without contrast APCs or paid through the imaging without contrast composite APCs when these services are furnished at an excepted off-campus PBD. Rural SCHs have historically received special payment treatment under OPPS to account for their higher costs and the disproportionately harmful impact that payment reductions could have on them. Therefore, CMS’s final volume control method policy will only impact imaging without contrast services furnished in excepted off-campus PBDs that are billed with the “PO” modifier. To support this policy, CMS explains that the agency continues to see growth in the volume of certain outpatient department services driven by site of service payment differentials. CMS asserts that the volume increases are based on financial incentives tied to payment policy and not to clinical necessity.
Therefore, the agency will remove the site-of-service payment differential for imaging without contrast for x-rays, CTs, MRIs and DXA scans and will apply the MPFS equivalent payment rate to those services when performed in the outpatient department (except at rural SCHs). The list of affected APCs can be found on page 440, Table 82: Proposed APCs Newly Paid the PFS-Equivalent Rate for Services Provided at Excepted Off-Campus PBDs for CY 2027.
OPPS Payments for Software as a Medical Service (SaMS) – p. 919
During last year’s OPPS rulemaking cycle, CMS sought comment from stakeholders on payment methodologies for software as a service (SaaS) technology. The agency hoped to gather information that would allow it to develop an appropriate and fair payment structure for these evolving technologies. In this year’s final rule, CMS finalized the following interim payment policies as they continue to consider a longer-term payment methodology for this group of services: First, the agency changed the nomenclature for these services from SaaS to Software as a Medical Service (SaMS) to more accurately describe algorithm-based software services. Second, the agency created a new status indicator “O1” (SaMS, paid under OPPS; separate APC payment) to designate SaMS that are payable under the OPPS. Third, the agency finalized assignment of all SaMS assigned to status indicator “O1” to a new technology APC. Table 84 on page 892 of the final rule lists the CY 2027 proposed and final APC assignments for SaMS. For CY 2027, CMS kept the payment rates consistent with CY 2026 OPPS rates for SaMS assigned to status indicator “O1”.
CPT code 0898T - Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report currently maps to APC 5724 - Level 4 Diagnostic Tests and Related Services. The current national payment rate for APC 5724 is $877. For 2027, CMS finalized the mapping of CPT code 0898T to new technology APC 1510 – New Technology Level 10, with a payment rate that ranges from $801 to $900, and status indicator “O1”.
Expansion of Botulinum Toxin Injection Codes for Hospital Outpatient Department (OPD) Prior Authorization Process – p. 1,123
Using its authority to develop “methods for controlling unnecessary increases in the volume of covered outpatient department services,” the agency expanded the list of botulinum toxin injection services subject to prior authorization under the OPPS. Table 102 on page 1,137 lists the additional eight Botulinum Toxin injection codes that require prior authorization beginning with service dates on or after July 1, 2027. Adding these procedures signals CMS’ intent to continue expanding the use of prior authorization in traditional Medicare.
As background, starting with the CY 2020 payment year, CMS established prior authorization processes for select procedures performed in the hospital outpatient department. The procedures captured under the prior authorization process include a broad range of service categories including blepharoplasty (eye lid repairs), rhinoplasty (nasal surgeries), ablation of veins, cervical fusion, implantation of neurostimulators, and injections of botulinum toxin. Table 103, starting on page 1,137, lists all the procedures, with corresponding CPT codes that are subject to prior authorization policy.
[1] Definition of status indicator J1: Paid under OPPS; all covered part B services on the claim are packaged with the primary "J1" service for the claim, except services with OPPS status indictor of "F', "G", "H", "L", and "U"; ambulance services, diagnostic and screen mammography, rehabilitation therapy services, services assigned to a new technology services, services assigned to a new technology APC, self-administered drugs, all preventive services, and certain part B inpatient services.